INTRODUCTION
Cardiac arrest (CA) is a major cause of death and disability in the developed world. In all, 1 out of 1,000 adults in the United States experiences CA every year. 1 Thanks to improved cardiopulmonary resuscitation (CPR) techniques and the widespread adoption of therapeutic hypothermia as a treatment option in recent years, survival rates after CA/CPR have improved. Overall survival is now above 20% in specialized centers, 1,2 which puts new emphasis on the significant cognitive problems many patients face after CA. The majority of survivors show signs of decreased memory or executive cognitive function, which is a cause of significant and sustained disability for many. 2, 3 The memory impairment is believed to be caused by neuronal death and atrophy of the ischemia-sensitive hippocampus, which has a central role in acquisition of new memories. 4 Even relatively brief periods of global ischemia cause a distinct pattern of brain injury in surviving patients, consisting of selective and delayed death of neurons within ischemia-sensitive areas, mostly the hippocampus and basal ganglia. 5 Neuronal death is delayed by several days after CA/ CPR, 6 which offers a unique window of opportunity for therapeutic interventions. At the same time, drug application is possible very early after resuscitation from CA, as trained medical personal is at the patient's side during resuscitation. Unfortunately, however, efforts to capitalize on the potential for preventing delayed neuronal death after CA/CPR are hampered by a lack of understanding of underlying mechanisms. No specific treatment options are therefore available for survivors of CA/CPR beyond hypothermia.
Brain inflammation is increasingly recognized as a critical component of brain injury. Microglia, the brain resident immune cells, are activated in response to injury and orchestrate the brain's inflammatory response. Microglia are activated after CA/CPR and migrate to injured brain regions where they remain activated for many weeks 7 and may contribute to delayed neuronal death. Accordingly, studies using the antibiotic minocycline, a nonspecific inhibitor of inflammation, suggest, albeit inconsistently, that antiinflammatory strategies may improve neuronal survival after global ischemia. 8, 9 However, few investigations have carefully evaluated the role of microglia in delayed neuronal death after CA/CPR.
We set out to investigate whether inhibition of a proinflammatory microglial enzyme, soluble epoxide hydrolase (sEH), after CA/ CPR can reduce activation of microglia and subsequently reduce neuronal death in the hippocampus. Soluble epoxide hydrolase metabolizes eicosatrienoic acids, cytochrome P450 epoxygenase produced metabolites of arachidonic acid, which have antiinflammatory and neuroprotective properties. 10 The sEH activity contributes to brain inflammation after stroke 11 and pharmacologic inhibition or genetic deletion of sEH consequently reduce infarct size after experimental stroke.
It remains unclear, however, if sEH also contributes to activation of neurotoxic microglia and subsequent neuronal death after CA/CPR and whether inhibition of sEH might thus be beneficial. In this study, we therefore examined whether the clinically relevant application of an sEH inhibitor after successful resuscitation from experimental CA can suppress inflammation and activation of microglia in the ischemia-susceptible hippocampus as well as improve neuronal survival and subsequently enhance memory function.
MATERIALS AND METHODS

Experimental Animals
All experimental protocols were performed in accordance with the National Institutes of Health guidelines for the care and use of animals in research and approved by the Institutional Animal Care and Use Committee at Oregon Health and Science University. Experimental animals were randomized to treatment groups. The experimenters were blinded to assigned treatment throughout all experiments and analyses.
Cardiac Arrest and Cardiopulmonary Resuscitation
Adult (20 to 25 g body weight) male C57BL/6 mice (Charles River Laboratories International, Wilmington, MA, USA) were subjected to CA/ CPR as previously described.
14 Briefly, mice were anesthetized with isoflurane (3% for induction, 1.5% to 2% for maintenance) in oxygenenriched air and orally intubated with a 22-G catheter. Mechanical ventilation was maintained at a rate of 150 breaths/min using a mouse ventilator (Minivent; Hugo Sachs Elektronik, March-Hugstetten, Germany). Core body temperature and head temperature were monitored throughout the experiment using temperature probes inserted into the rectum and left temporalis muscle, respectively, and controlled with a heating lamp and heating pad. Electrocardiogram (EKG) was monitored continuously with subcutaneous needle electrodes. Cardiac arrest was induced by injecting 50 mL ice-cold 0.5 mol/L potassium chloride into a PE-10 catheter inserted into the right internal jugular vein and confirmed by EKG asystole. During CA, head temperature was maintained at 38.9 ± 0.02 1C while body temperature was allowed to decrease to 29.9±0.03 1C. The CPR was initiated after 8 minutes of CA by injection of 0.5 to 1 mL of epinephrine solution (16 mg epinephrine/mL) and chest compressions at a rate of 300/min. Ventilation was resumed with 100% oxygen at a rate of 200/min. Return of spontaneous circulation (ROSC) was assessed by reappearance of electrical activity on the EKG monitor and observation of visible cardiac contractions. Animals were excluded from the study if ROSC was not achieved within 2 minutes.
In all, 5 mg/kg 4-phenylchalcone oxide (4-PCO, Enzo Life Sciences, Farmingdale, NY, USA) or vehicle (dimethylsulfoxide, DMSO) was diluted in 500 mL sterile 0.9% saline and administered by intraperitoneal injection 5 minutes after ROSC. Injections were repeated 24 hours later in animals scheduled for 3-day survival after CA/CPR.
Additional animals underwent sham surgery. These animals were instrumented and monitored as above, but no potassium chloride or epinephrine was injected.
A separate group of mice (n ¼ 4 per treatment) was instrumented with a PE-10 catheter in the right femoral artery before induction of CA to allow continuous monitoring of arterial blood pressure throughout the experiment. Blood samples were taken 10 minutes before CA and 35 minutes after ROSC to measure arterial blood gases, pH, potassium, lactate, and glucose levels.
Histologic Analysis
One (n ¼ 5 per treatment) or three (n ¼ 11 vehicle, n ¼ 12 4-PCO) days after CA/CPR, mice were deeply anesthetized with isoflurane and transcardially perfused with 0.9% saline followed by 4% paraformaldehyde. Brains were embedded in paraffin and 6 mm coronal sections were cut through the dorsal hippocampus. Sections were stained with hematoxylin and eosin (H&E) for analysis of neuronal death. The hippocampal CA1 region was analyzed at three levels, 100 mm apart, starting at À 1.5 mm from bregma. Nonviable neurons were identified by bright pink eosinophilic cytoplasm and a dark pyknotic nucleus. Viable as well as nonviable neurons were counted in three microscopic fields per section, and the percentage of nonviable neurons was averaged for three sections per animal, as previously described. 14 
Fluorojade B Staining
We additionally used Fluorojade B staining to identify dead and dying neurons in hippocampal CA1 3 days after CA/CPR. Deparaffinized sections adjacent to the ones used for H&E were stained for 20 minutes in 0.0004% Fluorojade B solution (EMD Millipore, Billerica, MA, USA) after 10 minutes incubation with 0.06% potassium permanganate. The density of Fluorojade B-positive dead/dying neurons in the CA1 regions of both hemispheres was assessed at Â 40 magnification using newCAST software (Visiopharm, Hørsholm, Denmark). Cells were counted in an average of eight counting frames (50 Â 50 mm) per CA1 region, which were selected by systematic uniform random sampling.
Immunohistochemistry
Adjacent hippocampal sections were stained for activated microglia using a Mac-2 antibody (Cedarlane, Burlington, NC, USA) that recognizes galectin-3, which is expressed by activated microglia. 15 Sections were deparaffinized and stained overnight with Mac-2 antibody (1:200), followed by incubation with a biotin-labeled goat-anti-rat secondary antibody (1:150) and Cy-3 linked streptavidin (1:700; both from GE Healthcare, Piscataway, NJ, USA). These conditions allow selective staining of activated microglia only, with no Mac-2-positive cells apparent in naïve or sham-operated animals. Photomicrographs of Mac-2-stained sections were obtained at low magnification ( Â 5). For analysis of microglial activation, ImageJ software (National Institutes of Health) was used to quantify the percentage of pixels above background staining (thresholded area) in a region of interest manually drawn around the hippocampus (see Figure 1 ) on three coronal sections adjacent to the sections used for cell death analysis.
Quantitative RT-PCR
Mice were deeply anesthetized and transcardially perfused with 0.9% saline 1 day after CA/CPR (n ¼ 5 vehicle, n ¼ 6 4-PCO) or sham surgery (n ¼ 5). Brains were removed, hippocampi dissected, and snap frozen in liquid nitrogen. RNA was extracted using RNA STAT-60 (Amsbio LLC, Lake Forest, CA, USA) and cDNA transcribed using RETROscript Kit (Life Technologies, Grand Island, NY, USA) after a DNAse digestion (Ambion DNA-free, Life Technologies). Quantitative PCR was performed on an ABI7000 real-time PCR system using SYBR Green Master Mix (Life Technologies). Gene expression was normalized using 18S and hypoxanthine phosphoribosyltransferase as reference genes.
Analysis of Nuclear Factor-kB Activity
Mice were deeply anesthetized and transcardially perfused with 0.9% saline 24 hours after CA/CPR (n ¼ 3 per treatment) or sham surgery (n ¼ 2). Brains were removed, hippocampi dissected, and hippocampal nuclear proteins isolated immediately using Nuclear Extract Kit (Active Motif, Carlsbad, CA, USA) according to the manufacturer's instructions. Protein concentration was measured by Bradford test (Bio-Rad, Hercules, CA, USA). Equal amounts of nuclear proteins were used to measure binding of nuclear Nuclear Factor-kB (NFkB) p65 to NFkB consensus DNA sequence using a TransAM NFkB p65 ELISA kit (Active Motif), according to the manufacturer's instructions.
Isolation of Microglia from Adult Mouse Brain After Cardiac Arrest/ Cardiopulmonary Resuscitation by Magnetic Bead-Assisted Cell Sorting
Naïve mice (n ¼ 3) and mice exposed to CA/CPR were perfused with cold phosphate-buffered saline 1 (n ¼ 3 per treatment) or 3 (n ¼ 3 per treatment) days later, and the brains were removed and minced. Singlecell suspension was created using enzymatic digestion and mechanical disruption (Neural Tissue Dissociation Kit; Miltenyi Biotec, Auburn, CA, USA). Myelin was removed and CD11b-positive cells (microglia) were enriched using subsequent positive and negative selection steps with antibody-coated magnetic beads (Miltenyi Biotec). Cells isolated from three animals per treatment group were pooled for isolation of RNA and gene expression analysis. RNA was isolated using TrizolLS (Life Technologies) and RNeasy spin columns (Qiagen, Valencia, CA, USA). DNAse digestion and quantitative RT-PCR were performed as described above.
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Fear Conditioning
We used a fear conditioning paradigm to assess long-term deficits in memory and learning after CA/CPR. An additional cohort of mice was followed for 10 days after CA/CPR. During this time, mice received daily intraperitoneal injections of vehicle (n ¼ 7) or 4-PCO (n ¼ 9), with the first injection administered 5 minutes after ROSC. On day 8 or 9 after CA/CPR, mice underwent training for contextual fear conditioning using one trial of a tone-footshock pairing, as previously described. 16 In brief, mice were individually placed in the conditioning chamber for 2 minutes before the onset of the conditioned stimulus, a tone that lasted for 30 seconds at 2,800 Hz and 85 db. The last 2 seconds of the conditioned stimulus were paired with the unconditioned stimulus, 0.35 mA of continuous footshock. After an additional 30 seconds in the chamber, the mice were returned to their home cage. Conditioning was assessed 24 hours later by scoring freezing behavior, which is defined as complete lack of movement except respirations, in intervals of 5 seconds. Contextual conditioning, which represents hippocampus-dependent memory formation, 16 was assessed by scoring freezing evoked by reexposure to the conditioning chamber (without tone or footshock). Cued conditioning, which relies more on extrahippocampal pathways and can be acquired in the presence of hippocampal injury, was also assessed. To test cued conditioning, freezing behavior was scored in response to reexposure to the tone (cue) in a novel chamber.
Data Analysis and Statistics
SigmaStat software (Systat Software Inc., Chicago, IL, USA) was used for statistical analysis. Groups were compared by two-tailed unpaired Student's t-test or one-way analysis of variance (ANOVA) with post hoc Holm-Sidak method for multiple comparisons, as appropriate. Blood gas and physiologic variables as well as fear conditioning data were compared using two-way ANOVA for repeated measures and post hoc Holm-Sidak method for multiple comparisons. Data are presented as mean ± s.e.m. All experiments were conducted in a randomized and blinded manner.
RESULTS
Inhibition of Soluble Epoxide Hydrolase Reduces Delayed
Neuronal Death After Cardiac Arrest Neuronal death was delayed after CA/CPR. Few CA1 neurons showed signs of ischemic injury and death (eosinophilic cytoplasm and pyknotic nucleus) 1 day after CA/CPR, independent of treatment ( Figure 1A ). Three days after CA/CPR, neuronal death was widespread, with 52 ± 7% of CA1 neurons dead or dying in vehicle-treated mice ( Figure 1B ). Mice treated with 5 mg/kg intraperitoneal of sEH inhibitor 4-PCO after resuscitation experienced significant protection against ischemic cell death, exhibiting only 34 ± 4% of dead or dying CA1 neurons on day 3 ( Figure 1B ; Po0.05 compared with vehicle treatment). Protection against ischemic cell death of CA1 neurons by 4-PCO was also confirmed by FluoroJade B staining. The density of dead and dying CA1 neurons 3 days after CA/CPR was significantly lower in animals receiving 4-PCO (747±115 cells/mm 2 ) compared with vehicle (1,422 ± 264 cells/mm 2 , Po0.05; Figure 1C ). The 4-PCO treatment had no effect on vital signs or physiologic parameters during recovery from CA/CPR. Blood pressure and arterial blood gases (pH, PaCO 2 , PaO 2 , glucose, base excess, lactate, and potassium) were not different between vehicle and 4-PCO-treated mice (see Supplementary Table 1 ).
4-Phenylcalcone Oxide Treatment Prevents Hippocampal Memory
Deficit After Cardiac Arrest/Cardiopulmonary Resuscitation To determine whether the CA1 injury sustained after CA/CPR is functionally relevant, we used a fear conditioning paradigm to test learning and memory. We compared contextual and cued conditioning to assess whether mice were able to acquire new memory in a hippocampus-dependent (contextual) versus hippocampus-independent (cued) task 8 to 9 days after CA/CPR. Twoway repeated measures ANOVA (drug treatment; contextual or cued test) revealed a significant test Â drug interaction (P ¼ 0.017). Further analysis of the interaction showed that vehicle-treated mice exhibited significantly reduced freezing behavior in the contextual versus cued conditioning test (42 ± 4% freezing to context versus 69 ± 4% to cue, Po0.05; Figure 2A ). This suggests that vehicle-treated mice sustained a selective deficit of hippocampus-dependent contextual learning after CA/CPR, in line with their significant CA1 injury. In contrast, 4-PCO-treated mice froze as much in response to context as to cue (57 ± 4% context, 62 ± 4% cue, P ¼ 0.4; Figure 2A ), suggesting that 4-PCO protected against the development of the hippocampus-specific learning deficit. Baseline freezing behavior in a novel environment was not different between treatment groups. To more closely examine memory function on the level of the individual mouse, we additionally compared the difference between freezing response to cue versus context in each individual. We found that while vehicle-treated mice consistently exhibited a deficit in contextual compared with cued freezing (27 ± 4% difference), this deficit was absent in 4-PCO-treated mice (5±6% difference, Po0.05; Figure 2B ). This suggests that 4-PCO not only reduces neuronal death after CA/CPR, but also protects hippocampal function, and that this protection persists beyond the early recovery period.
Microglial Activation is Increased Relative to Neuronal Death After 4-Phenylchalcone Oxide Treatment
We used immunolabeling for galectin-3/Mac-2, a marker of activated microglia, to assess the microglial response to CA/CPR. No Mac-2-positive activated microglia were present in hippocampus of mice after sham surgery. One day after CA/CPR, Mac-2 positive, phenotypically activated microglia with plumb cell bodies and short processes began to appear in the injured hippocampus, most pronounced in the area of the dentate gyrus. Microglial activation increased over time and was much more pronounced 3 days after CA/CPR, when Mac-2-positive microglia were present throughout the CA1 area and the dentate gyrus ( Figure 3B ). Activated microglia are thought to contribute to delayed neuronal death after CA/CPR by releasing neurotoxic mediators including pro-inflammatory cytokines. Accordingly, we expected that the number of dead CA1 neurons on day 3 would increase as more Mac-2-positive activated microglia appear in the hippocampus. We found that CA1 death and microglial activation (Mac-2-positive area) were indeed correlated on day 3 in both treatment groups with R 2 values of 0.50 and 0.64, respectively. However, the intensity of microglial activation on day 3 was similar in vehicle and 4-PCO-treated animals ( Figure 3A) , despite the significant reduction in neuronal death seen in 4-PCO-treated mice. We interpreted this finding to suggest that the relationship between activated microglia and injured neurons after CA/CPR is more complex than predicted by our initial hypothesis that more activated microglia would cause more neuronal death. To begin to better understand this relationship, we therefore assessed the extent of microglial activation relative to neuronal death in each animal. We found that microglial activation was significantly more pronounced relative to the severity of neuronal death in 4-PCOtreated animals ( Figures 3C and 3D ). This association of increased microglial activation and reduced CA1 death led us to speculate that hippocampal neuronal death may have been reduced in 4-PCO-treated mice because microglia were rendered less toxic while phenotypic activation of microglia remained unchanged.
4-Phenylchalcone Oxide Induces an Anti-Inflammatory Phenotype in Hippocampal Microglia After Cardiac Arrest
To address whether 4-PCO changed the inflammatory milieu created by activated microglia after CA/CPR, we next compared activation of proinflammatory transcription factor NF-kB and expression of inflammatory cytokines between vehicle and 4-PCOtreated mice. The NFkB p65 DNA binding activity was more than fourfold increased in hippocampal nuclear extracts from vehicletreated mice 1 day after CA, compared with sham surgery (Po0.05; Figure 4A ). In contrast, NFkB activation was significantly suppressed in 4-PCO-treated mice ( Figure 4A , Po0.05). Gene expression of NFkB regulated inflammatory cytokines tumor necrosis factor (TNF)-a as well as interleukin (IL)-1b and IL-10, but not inducible nitric oxide synthase (iNOS) was significantly increased in hippocampus of mice 1 day after CA/CPR compared with sham ( Figure 4B) . Surprisingly, however, despite reduced NFkB activation, mRNA expression of proinflammatory cytokines TNF-a and IL-1b and iNOS was not altered by 4-PCO treatment. In contrast, antiinflammatory IL-10 was selectively upregulated in hippocampus of 4-PCO-treated animals ( Figure 4B , Po0.05). To confirm that microglia are the cells responsible for increased cytokine expression after CA/CPR, we isolated microglia from mouse brains 1 ( Figure 4C ) or 3 days ( Figure 4D ) after CA/CPR and analyzed their gene expression. We found that cytokine expression patterns in isolated microglia were very similar to those in total hippocampus, supporting that microglia are the main producers of cytokines after CA/CPR. Cytokine expression in microglia was strongly upregulated 1 day after CA/CPR and persisted on day 3. Similar to the effect seen in whole hippocampus, 4-PCO treatment selectively increased expression of antiinflammatory and neuroprotective IL-10 in microglia without changing expression of IL-1b or iNOS. Expression of TNF-a was transiently increased in microglia from 4-PCO-treated mice on day 1 only (Figures 4C and 4D ).
DISCUSSION
Our study has three main findings. First, CA/CPR in our mouse model causes early hippocampal inflammation and activates microglia, followed by delayed neuronal death in the CA1 region 3 days after the insult. Second, this delayed neuronal death can be Protective microglia reduce injury after cardiac arrest J Wang et al significantly reduced, and hippocampus-dependent memory function protected, by an inhibitor of sEH administered after successful resuscitation, a clinically relevant treatment regimen.
Third, sEH inhibition induces expression of IL-10 in the hippocampus after CA/CPR, which may reduce microglial toxicity and contribute to improved neuronal survival. The pronounced increase in the number of Mac-2 expressing activated microglia that we saw in the hippocampus over the first days after CA/CPR is in line with other studies using models of global ischemia and reperfusion that find a similarly brisk response from microglia with significant proliferation in ischemia-sensitive areas 7, 15 and activation that is sustained for many weeks after the insult. 17 Resting microglia constantly survey their environment with their highly mobile processes, sensing input from neurons under their guard. 18 Ischemia/reperfusion injury causes the release of danger-associated molecules such as heatshock proteins from injured neurons, which are recognized by tolllike receptors on microglia and classically induce an NFkBdependent increase in transcription of IL-1b, TNF-a, and related cytokines. 19 The NFkB activation and increased hippocampal cytokine transcription in our study support that this pathway is relevant after CA/CPR. Traditionally, microglial activation is seen as part of a death pathway after ischemia/reperfusion as unopposed microglial activation in response to sterile injury exacerbates damage and causes bystander death of healthy or mildly injured neurons. 20 This notion is further supported by the fact that blocking inflammatory cytokines typically produced by activated microglia, such as TNF-a 21 and IL-1b 22 reduces stroke injury. In contrast, however, more recent work points at a significantly more complex role of microglia, which can act as both detrimental and supportive players after ischemia: selective ablation of proliferating microglia, for example, exacerbated stroke injury. 23 Similarly, suppression of microglial activation after CA/CPR has lead to mixed results, with some studies finding improved neuronal survival when antiinflammatory agents are provided, 24 whereas there is no effect in other studies. 25 Inhibition of sEH in our study reduced neuronal death without reducing the number of activated microglia, suggesting that neuronal death is not always a necessary consequence of microglial activation. Rather, there may be less toxic-or even supportive-types of activated microglia that are preferentially induced by sEH inhibition after CA/CPR.
It is increasingly recognized that myeloid cells outside the brain, which are related to microglia, such as blood-borne monocytes, can assume different activated phenotypes depending on the activating stimulus. Some of the phenotypes assumed in response to 'alternative' activation have enhanced capacity for phagocytosis, which is beneficial during clean-up, or even produce antiinflammatory mediators, which may help terminate the inflammatory response. 26 Early evidence supports that microglia as well can assume at least two different phenotypes, the classically activated microglia that produced toxic TNF-a, IL-1b, and nitric oxide as well as an alternatively activated microglial phenotype that produces IL-10. 27 The selective increase of IL-10 in response to sEH inhibition in our study may be evidence of such alternative activation of microglia, which adds to the emerging notion that microglia are not always and exclusively toxic, but can be induced to assume a more nurturing, neuroprotective phenotype. Further study is needed to more fully characterize this potentially beneficial microglial phenotype and define how it can be induced by sEH inhibition.
Soluble epoxide hydrolase is a proinflammatory enzyme widely expressed in the brain. 12 Inhibition of sEH reduces systemic inflammation and blocks activation of NFkB. 28 Similarly, inhibition of sEH reduces infarct size after ischemic stroke. 12 The reduction in ischemic injury by sEH inhibition may partly be a direct cytoprotective effect, as neurons themselves express sEH and sEH inhibitors reduce death in neuronal cultures after in vitro ischemia. 29 The situation in vivo is more complex, however, as ischemia induces a significant inflammatory response, which contributes to injury. Accordingly, genetic deletion of sEH causes clear reduction in brain inflammation after stroke, along with reduced infarct size. 11 Our current study suggests that sEH inhibition alters microglial gene expression patterns. This appears to be a specific effect rather than a reflection of overall reduced injury, as the number of activated microglia was unchanged and the expression of proinflammatory cytokines was unaltered. Activation of NFkB after ischemia was clearly suppressed by sEH inhibition in the current study, which is in line with studies of sEH inhibition in systemic inflammation. 28 However, transcription of NFkB regulated inflammatory cytokines IL-b and TNF-a unexpectedly remained unaltered while antiinflammatory IL-10 was increased. It is unclear why reduced NFkB activation did not cause decreases in cytokine transcription in 4-PCO-treated animals. Additional transcription factors such as activator protein (AP)-1, which regulates TNF-a transcription, are activated after ischemia. Activity of AP-1 increases in the CA1 early after global ischemia. 30 In a recent study of neonatal hypoxia/ischemia, inhibition of NFkB was strongly neuroprotective while expression of proinflammatory cytokines was maintained, 31 resembling our current findings in the 4-PCO group. The sustained TNF-a expression was caused by AP-1 activation and increased further when NFkB was blocked in that study. While we have not tested activation of AP-1 in our model, it is conceivable that 4-PCO may in a similar manner block NFkB while maintaining AP-1-dependent transcription of inflammatory cytokines. An additional possibility is that noncanonical NFkB signaling might contribute to cytokine expression after CA/CPR. We measured only the p65/Rel-A subunit of NFkB, which is activated in the canonical pathway. There is some evidence that noncanonical NFkB signaling pathways involving subunits p52 and Rel-C can be activated after cerebral ischemia.
32 It remains to be tested whether noncanonical NFkB activation takes place after CA/CPR and may be involved in sustaining cytokine transcription. Further study is needed to fully unravel the signaling pathways involved in the differential regulation of cytokines by 4-PCO after CA/CPR. As the number of microglia that can be isolated from adult mouse brain is limited, we focused our study on mRNA expression rather than protein levels to be able to assess several different cytokines in a limited sample. This lack of protein expression data is a limitation of our study. In light of the complex regulation of cytokine expression by 4-PCO suggested in the current study, future studies should investigate effects of 4-PCO on cytokine expression on the protein level.
Interleukin-10 is a neuroprotective, antiinflammatory cytokine that is expressed by most immune cells, including myeloid cells such as microglia. 33 It is traditionally seen as an antiinflammatory cytokine that can inhibit proliferation of T cells and production of proinflammatory cytokines. It also inhibits NFkB activation, 34 which may have contributed in a negative feedback loop to the reduced levels of nuclear NFkB p65 we observed in 4-PCO-treated mice. Production of IL-10 protects from fatal systemic inflammation in sepsis, 34 similar to the protection that is afforded by sEH inhibition in septic shock, 35 and IL-10-deficient mice have increased mortality from endotoxemia. As expression of proinflammatory cytokines was unchanged in 4-PCO-treated mice, it is less likely that the antiinflammatory action of IL-10 is critical for neuroprotection and improved functional outcome after inhibition of sEH. In addition to its antiinflammatory capacity, IL-10 is also directly neuroprotective, increasing AKT phosphorylation and reducing oxygen-glucose deprivation induced death in cultured neurons 36 as well as protecting neurons against glutamate toxicity. 37 This direct cytoprotection involves IL-10 receptor-dependent activation of the Jak/STAT and AKT pathways leading to increased expression of antiapoptotic Bcl-2 family members. 36, 37 Inhibition of sEH increases Bcl-2 expression in diabetic nephropathy, 38 suggesting that IL-10-dependent upregulation of antiapoptotic mediators may be one of the mechanisms by which inhibitors of sEH are protective. Both the antiinflammatory and neuroprotective effect may contribute to the benefits afforded by IL-10 after ischemia in vivo. IL-10
